Home
RYTM
RYTM News

Latest Rhythm Pharmaceuticals Inc. (RYTM) News on February 22, 2025

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

Investor's Business Daily

19 hours ago

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

2 days ago

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

GlobeNewswire

9 days ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February

GlobeNewswire

17 days ago

Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February

Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet

Zacks

25 days ago

Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.

a month ago

Exploring High Growth Tech Stocks in January 2025

Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?

Zacks

a month ago

Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

GlobeNewswire

a month ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential

TipRanks

2 months ago

Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential

MT Newswires

2 months ago

Jefferies Initiates Rhythm Pharmaceuticals at Buy With $80 Price Target

Exploring 3 High Growth Tech Stocks In The United States

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The United States

Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years

Simply Wall St.

2 months ago

Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years

MT Newswires

2 months ago

Rhythm Pharmaceuticals Gains FDA Approval for Expanded IMCIVREE Use

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Benzinga

2 months ago

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

GlobeNewswire

2 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

MT Newswires

2 months ago

Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals With Outperform Rating, $76 Price Target

Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities

TipRanks

3 months ago

Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities

MT Newswires

3 months ago

Rhythm Pharmaceuticals Says Imcivree Receives Expanded Marketing Authorization in UK

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

GlobeNewswire

3 months ago

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone

Investor's Business Daily

3 months ago

Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

GlobeNewswire

3 months ago

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

GlobeNewswire

3 months ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

3 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

High Growth Tech Stocks Featuring Three Prominent US Companies

Simply Wall St.

3 months ago

High Growth Tech Stocks Featuring Three Prominent US Companies

Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

3 months ago

Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

GlobeNewswire

4 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

Zacks

4 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

GlobeNewswire

4 months ago

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

GlobeNewswire

4 months ago

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Zacks

4 months ago

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

4 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?

Zacks

4 months ago

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

GlobeNewswire

4 months ago

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

GlobeNewswire

4 months ago

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

MT Newswires

4 months ago

Guggenheim Initiates Coverage on Rhythm Pharmaceuticals With Buy Rating, $70 Price Target

High Growth Tech Stocks to Watch in October 2024

Simply Wall St.

4 months ago

High Growth Tech Stocks to Watch in October 2024

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

4 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish

Insider Monkey

5 months ago

Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?

Zacks

5 months ago

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?

MT Newswires

5 months ago

HC Wainwright Initiates Rhythm Pharmaceuticals at Buy

MT Newswires

5 months ago

Rhythm Pharmaceuticals Shares Rise After JMP Securities Initiates Coverage at Outperform

MT Newswires

5 months ago

JMP Securities Initiates Rhythm Pharmaceuticals at Outperform

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

5 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Biotech Stock Near Buy Point Amid Impressive Sales Track Record

Investor's Business Daily

5 months ago

Biotech Stock Near Buy Point Amid Impressive Sales Track Record

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Investor's Business Daily

6 months ago

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Zacks

6 months ago

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

High Growth Tech Stocks To Watch In August 2024

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In August 2024

MT Newswires

6 months ago

Sector Update: Health Care Stocks Ease in Afternoon Trading

MT Newswires

6 months ago

Rhythm Pharmaceuticals Says US FDA Accepts its Supplemental New Drug Application for Imcivree

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

6 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Analysts Are Updating Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Estimates After Its Second-Quarter Results

Simply Wall St.

6 months ago

Analysts Are Updating Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Estimates After Its Second-Quarter Results

MT Newswires

7 months ago

Rhythm Pharmaceuticals' Q2 Net Loss Narrows, Revenue Rises

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Zacks

7 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

MT Newswires

7 months ago

Rhythm Pharmaceuticals Gets European Commission's Expanded Authorization for Obesity Drug

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

MT Newswires

7 months ago

Needham Adjusts Price Target on Rhythm Pharmaceuticals to $55 From $46, Maintains Buy Rating

MT Newswires

7 months ago

Rhythm Pharmaceuticals Doses First Patients in Trial of Hypothalamic Obesity Treatment

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

MT Newswires

7 months ago

Rhythm Pharmaceuticals Insider Sold Shares Worth $554,817, According to a Recent SEC Filing

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

MT Newswires

7 months ago

Rhythm Pharmaceuticals Appoints Alastair Garfield as Chief Scientific Officer

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

GlobeNewswire

7 months ago

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

MT Newswires

8 months ago

Rhythm Pharmaceuticals Says EMA Committee Backs Expanded Authorization for Obesity Drug

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

GlobeNewswire

8 months ago

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

8 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

GlobeNewswire

9 months ago

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

GlobeNewswire

9 months ago

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week

Simply Wall St.

9 months ago

While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week

MT Newswires

9 months ago

Rhythm Pharmaceuticals' Imcivree Gains UK Recommendation for Treating Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

GlobeNewswire

9 months ago

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

9 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript

Insider Monkey

9 months ago

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript

GuruFocus.com

9 months ago

Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...

Thomson Reuters StreetEvents

9 months ago

Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call

MT Newswires

10 months ago

Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell

GuruFocus.com

10 months ago

Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates

Zacks

10 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire

10 months ago

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

GlobeNewswire

10 months ago

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

Zacks

10 months ago

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline

Zacks

10 months ago

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

GlobeNewswire

10 months ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

GlobeNewswire

10 months ago

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

10 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Simply Wall St.

10 months ago

Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?

Zacks

10 months ago

Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

GlobeNewswire

a year ago

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

GlobeNewswire

a year ago

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Chief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM)

GuruFocus.com

a year ago

Chief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM)

Insider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 Shares

GuruFocus.com

a year ago

Insider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 Shares

Insider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ...

GuruFocus.com

a year ago

Insider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ...

Insider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM)

GuruFocus.com

a year ago

Insider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire

a year ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire

a year ago

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhythm Pharmaceuticals Full Year 2023 Earnings: Revenues Disappoint

Simply Wall St.

a year ago

Rhythm Pharmaceuticals Full Year 2023 Earnings: Revenues Disappoint

Share on Social Networks: